secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMED CORP (CHE)
CIK:        0000019584
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001562762-24-000179
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80
--------------------------------------------------------------------------------

- Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).
- VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.
- Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.
- FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.
- Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/0001562762-24-000179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/19584/000156276224000179/che-20240724x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer